aTyr Pharma, Inc.

aTyr Pharma announced a restructuring that will reduce its workforce by about 60% as it prioritizes efzofitimod and conserves capital.

The company expects the measures to lower annual operating expenses by about $13 million. San Diego-based aTyr Pharma announced a corporate restructuring and program prioritization centered on efzofitimod for interstitial lung disease.